Compugen Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
74
- Stock Symbol
-
CGEN
- Investments
-
3
- Share Price
-
$1.56
- (As of Wednesday Closing)
Compugen General Information
Description
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Contact Information
Website
www.cgen.comCorporate Office
- Azrieli Center
- 26 Harokmim Street Building D
- Holon 5885849
- Israel
Corporate Office
- Azrieli Center
- 26 Harokmim Street Building D
- Holon 5885849
- Israel
Compugen Stock Performance
As of 16-Jul-2025, Compugen’s stock price is $1.56. Its current market cap is $146M with 93.5M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.56 | $1.58 | $1.16 - $2.66 | $146M | 93.5M | 105K | -$0.16 |
Compugen Financials Summary
As of 31-Mar-2025, Compugen has a trailing 12-month revenue of $27.6M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 39,706 | 27,727 | 100,821 | (27,228) |
| Revenue | 27,589 | 27,864 | 33,459 | 7,500 |
| EBITDA | (12,712) | (12,268) | (34,591) | |
| Net Income | (14,145) | (14,231) | (18,754) | (33,694) |
| Total Assets | 115,443 | 114,995 | 121,334 | 94,176 |
| Total Debt | 2,771 | 2,912 | 1,351 | 1,925 |
Compugen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Compugen Comparisons
Industry
Financing
Details
Compugen Competitors (27)
One of Compugen’s 27 competitors is Bolt Biotherapeutics, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bolt Biotherapeutics | Formerly VC-backed | Redwood City, CA | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Compugen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Compugen Patents
Compugen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240425607-A1 | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer | Pending | 26-Jun-2023 | ||
| AU-2023275768-A1 | Anti-tigit antibody formulation | Pending | 26-May-2022 | ||
| EP-4531913-A1 | Anti-tigit antibody formulation | Pending | 26-May-2022 | ||
| EP-4245374-A2 | Pvrl2 and/or pvrig as biomarkers for treatment | Inactive | 18-Mar-2022 | ||
| EP-4245374-A3 | Pvrl2 and/or pvrig as biomarkers for treatment | Inactive | 18-Mar-2022 | G01N33/6857 |
Compugen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Compugen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Compugen Investments (3)
Compugen’s most recent deal was a Early Stage VC with Neviah Genomics. The deal was made on 12-Jan-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neviah Genomics | 12-Jan-2015 | Early Stage VC | Biotechnology | ||
| Neviah Genomics | 25-Jun-2012 | Joint Venture | Biotechnology | ||
| Evogene (Drug Discovery) | 01-Jan-2002 | Early Stage VC | Discovery Tools (Healthcare) |
Compugen ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
25.42 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Compugen Exits (3)
Compugen’s most recent exit was on 12-Jan-2015 from Neviah Genomics. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Neviah Genomics | 12-Jan-2015 | Completed |
|
||
| Neviah Genomics | 25-Jun-2012 | Completed |
|
||
| Evogene (Drug Discovery) | 01-Jan-2002 | Early Stage VC | Completed |
Compugen Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Neviah Genomics | Herzliya, Israel | 2012 |
Compugen FAQs
-
When was Compugen founded?
Compugen was founded in 1993.
-
Where is Compugen headquartered?
Compugen is headquartered in Holon, Israel.
-
What is the size of Compugen?
Compugen has 74 total employees.
-
What industry is Compugen in?
Compugen’s primary industry is Drug Discovery.
-
Is Compugen a private or public company?
Compugen is a Public company.
-
What is Compugen’s stock symbol?
The ticker symbol for Compugen is CGEN.
-
What is the current stock price of Compugen?
As of 16-Jul-2025 the stock price of Compugen is $1.56.
-
What is the current market cap of Compugen?
The current market capitalization of Compugen is $146M.
-
What is Compugen’s current revenue?
The trailing twelve month revenue for Compugen is $27.6M.
-
Who are Compugen’s competitors?
Bolt Biotherapeutics, Agenus, Dynavax Technologies, ImmunityBio, and Adaptimmune Therapeutics are some of the 27 competitors of Compugen.
-
What is Compugen’s annual earnings per share (EPS)?
Compugen’s EPS for 12 months was -$0.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
